The best guess approach to phase I trial designROSA, Daniela D; HARRIS, John; JAYSON, Gordon C et al.Journal of clinical oncology. 2006, Vol 24, Num 1, pp 206-208, issn 0732-183X, 3 p.Article

TCNU: a ray of hope for designer nitrosoureas?WORKMAN, P.European journal of cancer & clinical oncology. 1987, Vol 23, Num 12, pp 1823-1828, issn 0277-5379Article

Phase I trial of teroxironeNEIDHART, J. A; DEROCHER, D; GREVER, M. R et al.Cancer treatment reports. 1984, Vol 68, Num 9, pp 1115-1119, issn 0361-5960Article

PENTAMETHYLMELAMINE (PMM): PHASE I CLINICAL AND PHARMACOKINETIC STUDIES = PENTAMETHYLMELAMINE: ETUDE CLINIQUE PHASE I ET PHARMACOCINETIQUEMUINDI JRF; NEWELL DR; SMITH IE et al.1983; BRITISH JOURNAL OF CANCER; ISSN 0007-0920; GBR; DA. 1983; VOL. 47; NO 1; PP. 27-33; ABS. ENG; BIBL. 26 REF.; GRAPHArticle

A PHASE I AND CLINICAL PHARMACOLOGY STUDY OF INTRAVENOUSLY ADMINISTERED CARMINOMYCIN IN CANCER PATIENTS IN THE UNITED STATESCOMIS RL; ISSELL BF; PITTMAN K et al.1982; CANCER RES.; ISSN 0008-5472; USA; DA. 1982; VOL. 42; NO 7; PP. 2944-2948; BIBL. 15 REF.Article

Gemcitabine, paclitaxel, and piritrexim: A phase I studyLIU, Glenn; BAILEY, Howard H; ARZOOMANIAN, Rhoda Z et al.American journal of clinical oncology. 2003, Vol 26, Num 3, pp 280-284, issn 0277-3732, 5 p.Article

A phase I study of carboplatin concurrent with radiation in figo stage IIIB cervix uteri carcinomaDUENAS-GONZALEZ, Alfonso; CETINA, Lucely; SANCHEZ, Benito et al.International journal of radiation oncology, biology, physics. 2003, Vol 56, Num 5, pp 1361-1365, issn 0360-3016, 5 p.Article

Multi-Institutional Phase I Trials of Anticancer AgentsDOWLATI, Afshin; MANDA, Sudhir; GIBBONS, Joseph et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1926-1931, issn 0732-183X, 6 p.Article

PHASE I TRIAL OF INDICINE-N-OXIDE ON TWO DOSE SCHEDULES = ESSAI PHASE I DE L'INDICINE-N-OXYDE SELON DEUX PROTOCOLES DIFFERENTSTAYLOR S; BELT RJ; HAAS CD et al.1983; CANCER; ISSN 0008-543X; USA; DA. 1983; VOL. 51; NO 11; PP. 1988-1991; ABS. ENG; BIBL. 4 REF.; GRAPHArticle

FINAL REPORT ON THE UNITED STATES PHASE 1 CLINICAL TRIAL OF THE HYPOXIC CELL RADIOSENSITIZER, MISONIDAZOLE (R0-07-0582; NSC#261037)PHILLIPS TL; WASSERMAN TH; JOHNSON RJ et al.1981; CANCER; ISSN 0008-543X; USA; DA. 1981; VOL. 48; NO 8; PP. 1697-1704; BIBL. 15 REF.Article

A phase I clinical tolerance study of rDNA alpha₂ human interferon in patients with non-reticuloendothelial system malignancies = Etude clinique phase I de la tolérance de l'interféron leucocytaire humain alpha 2 recombinant chez les sujets ayant une affection maligne réticulo-endothélialeEDELSTEIN, M. B; SCHELLEKENS, H; LAURENT, T et al.European journal of cancer & clinical oncology. 1983, Vol 19, Num 7, pp 891-894, issn 0277-5379Article

Phase I study of a new anthraquinone derivative, mitoxantrone = Etude phase I d'une nouvelle anthraquinone, la mitoxantroneOGAWA, M; SAITO, T; WAKUI, A et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 85-91, issn 0146-0447Article

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial DiscussionsJENKINS, Valerie; SOLIS-TRAPALA, Ivonne; LANGRIDGE, Carolyn et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 61-68, issn 0732-183X, 8 p.Article

Translation of innovative designs into phase I trialsROGATKO, André; SCHOENECK, David; JONAS, William et al.Journal of clinical oncology. 2007, Vol 25, Num 31, pp 4982-4986, issn 0732-183X, 5 p.Article

90-Days mortality rate in patients treated within the context of a phase-I trial : How should we identify patients who should not go on trial?ARKENAU, Hendrik-Tobias; OLMOS, David; JOO ERN ANG et al.European journal of cancer (1990). 2008, Vol 44, Num 11, pp 1536-1540, issn 0959-8049, 5 p.Article

Final results of a phase I and pharmacokinetic study of _γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumorsJOHANSEN, Mary; ZUKOWSKI, Thomas; HOFF, Paulo M et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 5, pp 370-376, issn 0344-5704, 7 p.Article

Les essais thérapeutiques de phase I en cancérologie : enjeux éthiques : Ethique et essais cliniques = Phase I clinical trials in oncology: Ethical issuesGOLDWASSER, Francois.Thérapie (Paris). 2004, Vol 59, Num 4, pp 431-433, issn 0040-5957, 3 p.Conference Paper

Clinical outcome and prognostic factors for patients treated within the context of a phase I study : the Royal Marsden Hospital experienceARKENAU, H-T; OLMOS, D; ANG, J. E et al.British journal of cancer. 2008, Vol 98, Num 6, pp 1029-1033, issn 0007-0920, 5 p.Article

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumBART, Pierre-Alexandre; GOODALL, Ruth; LILJESTRÖM, Peter et al.Vaccine. 2008, Vol 26, Num 25, pp 3153-3161, issn 0264-410X, 9 p.Article

Presentation and subsequent publication rates of phase I oncology clinical trialsCAMACHO, Luis H; BACIK, Jennifer; CHEUNG, Alexander et al.Cancer. 2005, Vol 104, Num 7, pp 1497-1504, issn 0008-543X, 8 p.Article

Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumorsSAEKI, Toshiaki; EGUCHI, Kenji; TAKASHIMA, Shigemitu et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 5, pp 459-468, issn 0344-5704, 10 p.Article

Premières études chez l'homme d'un nouvel inotrope: INO 2628 CZ = A new inotropic agent, first clinical studies: INO 2628 CZTrenque, Thierry; Tillement, Jean-Paul.1991, 360 p.Thesis

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center InitiativeTSIMBERIDOU, Apostolia-Maria; ISKANDER, Nancy G; YANG YE et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6373-6383, issn 1078-0432, 11 p.Article

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistCINES, Douglas B; JENKINS, Julian M; WILLIAMS, Daphne et al.Blood. 2007, Vol 109, Num 11, issn 0006-4971, 4591-4592, 4739-4741 [5 p.]Article

A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agentRADEMAKER-LAKHAI, Jeany M; VAN DEN BONGARD, Desiree; PLUIM, Dick et al.Clinical cancer research. 2004, Vol 10, Num 11, pp 3717-3727, issn 1078-0432, 11 p.Article